DBV Technologies | DBVT - Current Assets

Stock Price
21.01
Daily Change
-0.46 -2.12%
Monthly
-8.15%
Yearly
411.16%
Q1 Forecast
20.91

DBV Technologies reported $88.88M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amarin USD 628.33M 21.52M Sep/2025
BioCryst Pharmaceuticals USD 355.68M 42.78M Sep/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
DBV Technologies USD 88.88M 32.36M Sep/2025
Esperion Therapeutics USD 360.46M 17.87M Sep/2025
Galectin Therapeutics USD 27.29M 1.83M Jun/2024
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
Insmed USD 1.79B 137.6M Dec/2025
Ionis Pharmaceuticals USD 2.52B 58.16M Sep/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
United Therapeutics USD 3.49B 332.9M Sep/2025